Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy – A Randomized, Controlled Trial: Complete Statistical AnalysisIndependent statistical analysis of RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RICHIndependent statistical analysis of Repair of Infected or Contaminated Hernias: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00617357).
- Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy: Complete Statistical AnalysisIndependent statistical analysis of Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03176472).
- Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ridge Preservation After Tooth Extraction Using Cortical Versus Cancellous Freeze Dried Bone Allograft: Complete Statistical AnalysisIndependent statistical analysis of Ridge Preservation After Tooth Extraction Using Cortical Versus Cancellous Freeze Dried Bone Allograft: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- RIDILOTT-DVTIndependent statistical analysis of Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03413618).
- Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease: Complete Statistical AnalysisIndependent statistical analysis of Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Rifaximin Therapy in Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Rifaximin Therapy in Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02342639).
- RIFL (Rigid and Flexing Laryngoscope) vs. Fiberoptic Bronchoscope: Complete Statistical AnalysisIndependent statistical analysis of RIFL (Rigid and Flexing Laryngoscope) vs. Fiberoptic Bronchoscope: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01965938).
- RIGHT: Rhythm ID Going Head-to-Head Trial: Complete Statistical AnalysisIndependent statistical analysis of RIGHT: Rhythm ID Going Head-to-Head Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00148954).
- RILECSUIndependent statistical analysis of Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine: primary endpoint results, effect estimate with confidence interval, sample-size…
- RiLEYIndependent statistical analysis of 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder: Complete Statistical AnalysisIndependent statistical analysis of Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00523718).
- Riluzole in the Treatment of Bipolar Depression: Complete Statistical AnalysisIndependent statistical analysis of Riluzole in the Treatment of Bipolar Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00544544).
- Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders: Complete Statistical AnalysisIndependent statistical analysis of Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- RIM4DMDIndependent statistical analysis of Rimeporide in Patients With Duchenne Muscular Dystrophy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02710591).
- RIPCOM1Independent statistical analysis of The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- RISEIndependent statistical analysis of Raising Insulin Sensitivity in Post Menopause: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02274571).
- RISEIndependent statistical analysis of Research Intervention to Support Healthy Eating and Exercise: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04353258).
- RISEIndependent statistical analysis of Rural Interventions for Screening Effectiveness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02795104).
- RISEIndependent statistical analysis of Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- RISE AdultIndependent statistical analysis of RISE Adult Medication Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01779362).
- RISE-MIndependent statistical analysis of Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03634800).
- RISE-UPIndependent statistical analysis of Risk Information and Skin-cancer Education for Undergraduate Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03979872).
- RISE+Independent statistical analysis of Testing the Efficacy and Mechanisms of an Adapted Resilience Building Intervention in People Aging With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Risk Identification of the GlucoTab System in Routine Use: Complete Statistical AnalysisIndependent statistical analysis of Risk Identification of the GlucoTab System in Routine Use: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02053077).
- Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins: Complete Statistical AnalysisIndependent statistical analysis of Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Risk Stratification to Promote Effective Shared Decision-Making for Colorectal Cancer Screening: Complete Statistical AnalysisIndependent statistical analysis of Risk Stratification to Promote Effective Shared Decision-Making for Colorectal Cancer Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma: Complete Statistical AnalysisIndependent statistical analysis of Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer: Complete Statistical AnalysisIndependent statistical analysis of Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar: Complete Statistical AnalysisIndependent statistical analysis of Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00176202).
- RITA-2Independent statistical analysis of Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- RITAPSIndependent statistical analysis of A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab and ABVD for Hodgkin’s Patients: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and ABVD for Hodgkin's Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00504504).
- Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom’s Macroglobulinemia: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM): Complete Statistical AnalysisIndependent statistical analysis of Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH): Complete Statistical AnalysisIndependent statistical analysis of Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01086540).
- Rituximab in Pretreated Elderly or Unfit B-CLL Patients: Complete Statistical AnalysisIndependent statistical analysis of Rituximab in Pretreated Elderly or Unfit B-CLL Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01576588).
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Rituximab in Treating Patients With Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab in Treating Patients With Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00003820).
- Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Rituximab or Zevalin – Efficacy Trial of Therapeutic Alternatives (RoZetta): Complete Statistical AnalysisIndependent statistical analysis of Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01662102).